The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended the approval of Opdivo plus platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account